Rethinking VMT

Article

During a press briefing held at the 4th COPHy congress in Budapest, Hungary, key opinion leaders discussed VMT and macular holes and how a new injectable drug could benefit patients. In this article, we will present the highlights of this meeting.

Related Videos
Kasperi Kankare at the iCare booth at ESCRS
Colman Cawe, director of fundraising and communications, Orbis UK
The slide reads, "ASRS 2023. What research do you find exciting or interesting? Hear what presenters and industry leaders have to say about the presentations at ASRS 2023."
The slide reads, "ASRS 2023. What research do you find exciting or interesting? Hear what presenters and industry leaders have to say about the presentations at ASRS 2023."
The slide reads, "ASRS 2023. What research do you find exciting or interesting? Hear what presenters and industry leaders have to say about the presentations at ASRS 2023."
Maria H. Berrocal, MD, speaks on a virtual call before the Women in Ophthalmology symposium in Marco Island, Florida
Fernando Arevalo, MD, PhD, FACS, FASRS, stands against a backdrop as he is interviewed at the 2023 ASRS annual meeting.
Related Content

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation

September 9th 2023

Orbis and Heidelberg Engineering announce new partnership at ESCRS congress

September 8th 2023

Impact of personalised faricimab dosing in neovascular AMD

September 7th 2023

BVI acquires Medical Mix, expanding its presence in Europe

September 6th 2023

Atsena Therapeutics doses first patient in Phase I/II clinical trial of ATSN-201 for treatment of x-linked retinoschisis

August 29th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation

September 9th 2023

Orbis and Heidelberg Engineering announce new partnership at ESCRS congress

September 8th 2023

Impact of personalised faricimab dosing in neovascular AMD

September 7th 2023

BVI acquires Medical Mix, expanding its presence in Europe

September 6th 2023

Atsena Therapeutics doses first patient in Phase I/II clinical trial of ATSN-201 for treatment of x-linked retinoschisis

August 29th 2023

RETFound: New AI model to detect retinal disease biomarkers developed by Moorfields Eye Hospital

September 14th 2023

ESCRS 2023: Ace Vision Group presents scientific data focused on laser scleral microporation

September 9th 2023

Orbis and Heidelberg Engineering announce new partnership at ESCRS congress

September 8th 2023

Impact of personalised faricimab dosing in neovascular AMD

September 7th 2023

BVI acquires Medical Mix, expanding its presence in Europe

September 6th 2023

Atsena Therapeutics doses first patient in Phase I/II clinical trial of ATSN-201 for treatment of x-linked retinoschisis

August 29th 2023
© 2023 MJH Life Sciences

All rights reserved.